Undisclosed small molecule inhibitor / Sitryx, Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics (Sitryx Press Release) - "The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells; Deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties; Exclusive license expands Boehringer’s preclinical immunology pipeline aiming to improve patient outcomes."

Licensing / partnership • Immunology • Inflammation